MTOR and cancer: Miyoshi and coworkers have analyzed the genome profiling of 78 LCNECs by targeted capture sequencing of all the coding exons of 244 cancer-related genes and observed: frequent inactivating mutations in TP53 (71%) and RB1 (26%); genetic alterations in PI3K/AKT/mTOR pathway [15%, including RICTOR (5%), PI3KCA (3%), PTEN (4%), AKT2 (4%) and mTOR (1%)]; activating mutations at the level of RTKs [FGFR1 (5%), KIT (4%), ERBB2 (4%), EGFR (1%)] and RAS pathways [KRAS (6%) and HRAS (1%)].